Hepatectomy for rapidly growing solitary liver metastasis from non-small cell lung cancer: a case report

Hakoda, Hiroyuki; Sekine, Yoshihiro; Ichimura, Hideo; Ueda, Kazumitsu; Aoki, Shigeo; Mishima, Hideyuki; Sako, Akihiro; Kobayashi, Keisuke; Sakamoto, Akiko; Satô, Yukio

doi:10.1186/s40792-019-0633-6

Cited by 8 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24 Nagashima et al and Hakoda et al also found that resection of liver metastases from NSCLC may offer the possibility of long-term survival. 25,26 Thus, the results of our study may be useful in making practical and informed clinical decisions, such as a more precise assessment of the prognosis of patients with metastasized PC tumors.…”

Section: Discussionmentioning

confidence: 90%

The Cancers-Specific Survival of Metastatic Pulmonary Carcinoids and Sites of Distant Metastasis: A Population-Based Study

Zhang

et al. 2021

Technol Cancer Res Treat

View full text Add to dashboard Cite

Background: Lung cancer is the leading cause of cancer-related deaths and pulmonary carcinoids (PCs) account for almost 2% of all pulmonary malignancies. However, few published articles have reported prognosis and related factors of pulmonary carcinoid patients. Material and Method: The Surveillance, Epidemiology, and End Results (SEER) database was used to collect data of patients diagnosed with metastatic PCs from 2010 to 2016. The prognosis and survival of these patients were compared by employing Cox proportional hazards and the Kaplan-Meier survival analysis. Results: A total of 1763 patients were analyzed. The liver (668, 25.6%) was shown to be the most common metastatic site in the isolated organ metastasis cohort, followed by the lung (636, 24.4%), bone (562, 21.6%), and brain (460, 17.6%). Among the patients, the tumor metastasized to a single distant site included the liver, bone, lung, and brain. Cancer-specific survival (CSS) in metastatic PCs is determined by the site of metastasis and the total number of such sites. Pulmonary carcinoid patients with isolated liver metastasis manifested more favorable survival rates in comparison to patients having isolated metastasis in the lung, brain, or bone. The median CSS was 45, 7, 6, 5 months ( P = 0.011). The number of distant metastatic sites and the location of distant metastasis were found to be independent risk factors for CSS. For patients with distant isolated metastasis, liver metastasis ( P < 0.0001) had better CSS in comparison to those with bone metastasis. When compared to patients whose carcinoids had metastasized to the bones, patients with a brain ( P = 0.273) or lung ( P = 0.483) metastasis had the same CSS. Conclusion: Cancer-specific survival in metastatic PCs depends on the site of metastasis and the total number of such locations. PC patients with isolated liver metastasis manifested more favorable survival in comparison to patients with isolated metastasis in the lung, brain, or bone.

show abstract

Section: Discussionmentioning

confidence: 90%

The Cancers-Specific Survival of Metastatic Pulmonary Carcinoids and Sites of Distant Metastasis: A Population-Based Study

Zhang

et al. 2021

Technol Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Hakoda et al [ 114 ] reported that hepatectomy of a solitary LM from NSCLC was the preferred management for a 74-year-old man with a stable condition. In a retrospective study conducted on 2038 patients who underwent NSCLC resection between January 1997 and December 2015, hepatectomy was as effective as a multimodal treatment for an oligometastatic hepatic recurrence of NSCLC.…”

Section: Prospective Preclinical and Clinical Strategies For Targetin...mentioning

confidence: 99%

Evolving landscape of treatments targeting the microenvironment of liver metastases in non-small cell lung cancer

Zhu,

Yu,

Tang

et al. 2024

Chinese Medical Journal

View full text Add to dashboard Cite

Liver metastases (LMs) are common in lung cancer. Despite substantial advances in diagnosis and treatment, the survival rate of patients with LM remains low as the immune-suppressive microenvironment of the liver allows tumor cells to evade the immune system. The impact of LMs on the outcomes of immune checkpoint inhibitors in patients with solid tumors has been the main focus of recent translational and clinical research. Growing evidence indicates that the hepatic microenvironment delivers paracrine and autocrine signals from non-parenchymal and parenchymal cells. Overall, these microenvironments create pre- and post-metastatic conditions for the progression of LMs. Herein, we review the epidemiology, physiology, pathology and immunology, of LMs associated with non-small cell lung cancer and the role and potential targets of the liver microenvironment in LM in each phase of metastasis. Additionally, we reviewed the current treatment strategies and challenges that should be overcome in preclinical and clinical investigations. These approaches target liver elements as the basis for future clinical trials, including combinatorial interventions reported to resolve hepatic immune suppression, such as immunotherapy plus chemotherapy, immunotherapy plus radiotherapy, immunotherapy plus anti-angiogenesis therapy, and surgical resection.

show abstract

“…Lung cancer can be divided into two categories: non-small cell lung cancer (NSCLC) and small cell lung cancer, and NSCLC account for approximately 85% of lung cancer cases, due to clinical manifestations and signs are not obvious, and about 40%-55% of these patients are advanced at the time of diagnosis 2 . The common sites of metastasis in advanced NSCLC are bone, brain, adrenal gland, and liver 3 . For advanced patients presenting with metastases, their median survival is 8–12 months, while in patients with metastases at common sites, the median Overall survival(OS) is only 3 months once liver metastases are diagnosed 4 , 5 .…”

Section: Introductionmentioning

confidence: 99%

Construction and validation of a nomogram for non small cell lung cancer patients with liver metastases based on a population analysis

Zhao

Dai

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Lung cancer is one of the most common malignancies in the United States, and the common metastatic sites in advanced non-small cell lung cancer (NSCLC) are bone, brain, adrenal gland, and liver, respectively, among which patients with liver metastases have the worst prognosis. We retrospectively analyzed 1963 patients diagnosed with NSCLC combined with liver metastases between 2010 and 2015. Independent prognostic factors for patients with liver metastases from NSCLC were identified by univariate and multivariate Cox regression analysis. Based on this, we developed a nomogram model via R software and evaluated the performance and clinical utility of the model by calibration curve, receiver operating characteristic curves, and decision curve analysis (DCA). The independent prognostic factors for NSCLC patients with liver metastases included age, race, gender, grade, T stage, N stage, brain metastases, bone metastases, surgery, chemotherapy, and tumor size. The area under the curve predicting OS at 6, 9, and 12 months was 0.793, 0.787, and 0.784 in the training cohort, and 0.767, 0.771, and 0.773 in the validation cohort, respectively. Calibration curves of the nomogram showed high agreement between the outcomes predicted by the nomogram and the actual observed outcomes, and the DCA further demonstrated the value of the clinical application of the nomogram. By analyzing the Surveillance, Epidemiology, and End Results database, we established and verified a prognostic nomogram for NSCLC patients with liver metastases, to personalize the prognosis of patients. At the same time, the prognostic nomogram has a satisfactory accuracy and the results are a guide for the development of patient treatment plans.

show abstract

Hepatectomy for rapidly growing solitary liver metastasis from non-small cell lung cancer: a case report

Cited by 8 publications

References 16 publications

The Cancers-Specific Survival of Metastatic Pulmonary Carcinoids and Sites of Distant Metastasis: A Population-Based Study

The Cancers-Specific Survival of Metastatic Pulmonary Carcinoids and Sites of Distant Metastasis: A Population-Based Study

Evolving landscape of treatments targeting the microenvironment of liver metastases in non-small cell lung cancer

Construction and validation of a nomogram for non small cell lung cancer patients with liver metastases based on a population analysis

Contact Info

Product

Resources

About